Catalyst Pharmaceuticals (NASDAQ: CPRX) stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE® and AGAMREE®.
The biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, marking another year of record growth.
Catalyst's flagship product, FIRDAPSE®, saw its net revenue climb 18.4% to $306 million for the full year, fueled by sustained organic growth. Additionally, the company's recently launched therapy, AGAMREE®, garnered $46 million in net revenue in 2024, reflecting its successful market adoption and strong commercial performance.
Buoyed by these impressive results and the continued momentum of its key products, Catalyst Pharmaceuticals provided an upbeat outlook for fiscal 2025. The company forecasted total revenues to be between $545 million and $565 million, highlighting its confidence in continued growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。